Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms, demonstrating modest cognitive decline reduction in clinical trials while presenting safety considerations including amyloid-related imaging abnormalities (ARIA), infusion reactions, and the need for careful patient selection and monitoring protocols.

EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease

EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection

EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment

EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help

EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease

EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease

EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas

Now Viewing

EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations

EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy

EP: 10.Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations

EP: 11.Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease

EP: 12.Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers

EP: 13.Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy

Video content above is prompted by the following:

• Please discuss the class and complete drug profile of amyloid-targeting therapies for Alzheimer disease, including their mechanisms of action, efficacy, and safety profiles.

Related Videos

Related Content

Advertisement

April 23rd 2025

EDs Struggle to Screen, Respond to Social Determinants of Health, Survey Finds

Giuliana Grossi

Emergency departments (ED) struggle to screen for social determinants of health, inhibiting quality care and impacting health disparities among vulnerable populations.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 23rd 2025

Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis

Brooke McCormick

Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

April 17th 2025

Frequent Use of Antibiotics Linked to Asthma, Allergies in Children

Julia Bonavitacola

Intellectual disabilities, food allergies, and asthma were all more common in children who took multiple courses of antibiotics before the age of 2 years.

Related Content

Advertisement

April 23rd 2025

EDs Struggle to Screen, Respond to Social Determinants of Health, Survey Finds

Giuliana Grossi

Emergency departments (ED) struggle to screen for social determinants of health, inhibiting quality care and impacting health disparities among vulnerable populations.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 23rd 2025

Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis

Brooke McCormick

Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

April 17th 2025

Frequent Use of Antibiotics Linked to Asthma, Allergies in Children

Julia Bonavitacola

Intellectual disabilities, food allergies, and asthma were all more common in children who took multiple courses of antibiotics before the age of 2 years.